We describe a new pathway signaling neutrophil (PMN) influx and damage to the airways that may play a role in chronic obstructive pulmonary disease (COPD). Chemical or enzymatic breakdown of collagen releases a tripeptide, PGP, and an acetylated form (N-?-PGP) that are chemotactic for PMN. Prolonged airway exposure to this peptide causes alveolar enlargement and right ventricular hypertrophy. Further- more, PGP is found in the airways of animals exposed to aerosolized endotoxin (LPS) and markedly contributes to PMN influx. The enzymatic production of PGP is a stepwise process initially involving matrix metalloproteases (MMP)-8 and/or MMP-9 with prolyl endopeptidase (PE), a serine protease, catalyzing the final reaction. We have also found that PGP is present in bronchoalveolar lavage fluid (BALF) and/or sputum from most COPD patients but not controls or asthmatics. Sputum from COPD patients but not control individuals also contains all the enzymatic machinery necessary for the ex vivo generation of PGP from purified collagen and such PGP production can be blocked by MMP-8 or MMP-9 inhibitors or by a PE- specific inhibitors. The macrolide trial currently being conducted by the COPD Clinical Research Network (CRN) offers a unique opportunity to study the role of PGP in airway inflammation in COPD. Measurement of PGP and N-?-PGP in the cohort of COPD patients recruited for this trial will provide information which could otherwise only be acquired by another large-scale clinical trial. The current period of enrollment for this trial affords an important window of opportunity, belying the time-sensitive nature of this proposal. Measurement of MMP and PE levels and activity in sputum will provide new and important information on the generation of PGP in COPD and identify possible new therapeutic targets against airway inflammation in this disease. Importantly, macrolide antibiotics have been identified as negative transcriptional regulators for MMPs. This is proposed to underly a possible therapeutic activity in chronic lung diseases such as COPD. Finally, this trial will enable us to test this hypothesis in a large cohort of COPD patients, both taking azithromycin and controls, thereby providing a scientific basis for the activity of macrolides in COPD. Our underlying hypothesis is that levels of N-?-PGP/PGP and the activity of enzymes that generate them, specifically MMPs and PE, are lower in patients with COPD taking azithromycin than in COPD patients on placebo and that this reduction will correlate with improvement in clinical endpoints in these patients.
Specific aims : 1. Measure levels of N-?-PGP/PGP and activity of PGP-generating enzymes, specifically MMP's and PE, in sputum of COPD patients taking azithromycin and in sputum of COPD patients taking placebo. 2. Compare the ability of sputum from COPD patients taking azithromycin to generate N-a- PGP/PGP ex vivo from collagen with sputum from COPD patients taking placebo. 3. Correlate levels of N-?-PGP/PGP and activity of PE in induced sputum with levels and activity in serum of COPD patients. COPD is now the fourth leading cause of death in the U.S. and is expected to be the third by 2020. This disease causes much human suffering as well as a large monetary burden. An understanding of COPD that leads to successful therapeutics has been hampered by a lack of biomarkers to diagnose and use as endpoints in clinical trials as well as a lack of a fundamental understanding of the disease process itself. If successful, the current proposal will yield fundamental insights into the disease process and a new and specific biomarker for COPD as well as suggesting new therapeutic targets.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL090999-04
Application #
7896680
Study Section
Special Emphasis Panel (ZHL1-CSR-H (M1))
Program Officer
Croxton, Thomas
Project Start
2007-08-10
Project End
2012-07-31
Budget Start
2010-08-01
Budget End
2012-07-31
Support Year
4
Fiscal Year
2010
Total Cost
$362,500
Indirect Cost
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Szul, Tomasz; Castaldi, Peter; Cho, Michael H et al. (2016) Genetic regulation of expression of leukotriene A4 hydrolase. ERJ Open Res 2:
Szul, Tomasz; Bratcher, Preston E; Fraser, Kyle B et al. (2016) Toll-Like Receptor 4 Engagement Mediates Prolyl Endopeptidase Release from Airway Epithelia via Exosomes. Am J Respir Cell Mol Biol 54:359-69
Noerager, Brett D; Xu, Xin; Davis, Virginia A et al. (2015) A Potential Role for Acrolein in Neutrophil-Mediated Chronic Inflammation. Inflammation 38:2279-87
Hahn, Cornelia S; Scott, David W; Xu, Xin et al. (2015) The matrikine N-?-PGP couples extracellular matrix fragmentation to endothelial permeability. Sci Adv 1:
Kong, Michele Y F; Whitley, Richard J; Peng, Ning et al. (2015) Matrix Metalloproteinase-9 Mediates RSV Infection in Vitro and in Vivo. Viruses 7:4230-53
Kong, Michele Y F; Whitley, Richard J; Peng, Ning et al. (2015) Addendum: Kong, M.Y.; Whitley, R.J.; Peng, N.; Oster, R.; Schoeb, T.R.; Sullender, W.; Ambalavanan, N.; Clancy, J.P.; Gaggar, A.; Blalock J.E. Matrix Metalloproteinase-9 Mediates RSV Infection in Vitro and in Vivo. Viruses 2015, 30, 7, 4230–4253. Viruses 7:5609
Koelink, Pim J; Overbeek, Saskia A; Braber, Saskia et al. (2014) Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease. Gut 63:578-87
Abdul Roda, Mojtaba; Sadik, Mariam; Gaggar, Amit et al. (2014) Targeting prolyl endopeptidase with valproic acid as a potential modulator of neutrophilic inflammation. PLoS One 9:e97594
Overbeek, Saskia A; Braber, Saskia; Koelink, Pim J et al. (2013) Cigarette smoke-induced collagen destruction; key to chronic neutrophilic airway inflammation? PLoS One 8:e55612
O'Reilly, Philip J; Jackson, Patricia L; Wells, J Michael et al. (2013) Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open 3:e004140

Showing the most recent 10 out of 24 publications